Sam Davis

We need an Innovation Review Voucher, where a USA innovator (not others) can apply, based on their innovation in a drug category or molecule, for super fast regulatory approval, AND a transferable and subdividable 3 year commercial exclusivity, which covers the structure and close derivatives. Applications would be 90 day decisions, with a standard that a reasonable person would conclude that the technology was used or copied by the entity. In practice, this should prevent USA innovation from being decimated via less funding flowing in (which hurts patients in the long run), and if the commercial delay is critically important the vouchers are tradeable, and can be granted to more than one party at the discretion of the holder, so patients are protected. Prob have like ARPA H like structure or some new DOC panel to do it.

There is vacuum of expertise on patent/IP strategy in life sciences. Don't assume the $2000/hr patent partner at a top firm is going offer sound strategy - in fact, b/c of the billable hour pressure, they may even lead you down the path of over-filing.

Missing from the narrative that the dominance of China biotech is great for the ecosystem/patients is the negative impact on scientific knowledge dissemination. Legislation needs to address China IP theft “fast follower” - the consequences are already showing up in the way innovators think about sharing, patenting and publishing. We publish & patent but are increasingly keeping more as trade secret. Fully agree w/Neil, Alexis and Ali